Tirzepatide Excites in Obesity Now Too, Says Lilly
The once-weekly investigational twincretin drug is in phase 3 development for obesity and under regulatory review, with a decision expected soon for type 2 diabetes.
Medscape Medical News
source https://www.medscape.com/viewarticle/972936?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/972936?src=rss
Comments
Post a Comment